Under the deal, Cyclenium’s CMRT Technology-derived QUEST Library and associated hit-to-lead optimization expertise will be combined with Haplogen’s haploid genetics technology and expertise in host target identification, validation and screening.
Cyclenium Pharma president and CEO Helmut Thomas said: "We are extremely excited about the potential of this research collaboration with Haplogen, the leader in applying cutting-edge haploid genetics technology for drug discovery.
"It was immediately apparent to us that Haplogen’s proven expertise and success in identifying and characterizing novel host factors together with our proprietary CMRT macrocyclic chemistry technology would be a powerful combination for the discovery and development of new therapeutic agents."
Initially, the firms will focus on certain anti-viral Haplogen targets, with targets in other therapeutic indications being phased-in as the research progresses.
Cyclenium specializes in the research and development of new drug candidates based on its proprietary macrocyclic chemistry technology.